Delivering Signal-Altering Bacterial Effector Proteins to Mammalian Cells Using Cell-Penetrating Peptide Technology by Dickson, Robert
Kennesaw State University
DigitalCommons@Kennesaw State University
Master of Science in Integrative Biology Theses Department of Ecology, Evolution, and OrganismalBiology
Summer 6-19-2019
Delivering Signal-Altering Bacterial Effector
Proteins to Mammalian Cells Using Cell-
Penetrating Peptide Technology
Robert Dickson
Follow this and additional works at: https://digitalcommons.kennesaw.edu/integrbiol_etd
Part of the Integrative Biology Commons
This Thesis is brought to you for free and open access by the Department of Ecology, Evolution, and Organismal Biology at
DigitalCommons@Kennesaw State University. It has been accepted for inclusion in Master of Science in Integrative Biology Theses by an authorized
administrator of DigitalCommons@Kennesaw State University. For more information, please contact digitalcommons@kennesaw.edu.
Recommended Citation
Dickson, Robert, "Delivering Signal-Altering Bacterial Effector Proteins to Mammalian Cells Using Cell-Penetrating Peptide




Kennesaw State University 
Thesis Dissertation 
 
Delivering Signal-Altering Bacterial Effector Proteins to Mammalian Cells Using Cell-













Author: Robert Luke Dickson 
Principle Investigator: Dr. Jonathan McMurry 
Committee Members: Dr. Jonathan McMurry, Dr. Carol Chrestensen, Dr. Scott Nowak 




TABLE OF CONTENTS 
 
i.  ABSTRACT…………………………………………………….……………6 
1.  INTRODUCTION…………………………………………………………...7 
1.1 Type III Secretion Systems…………………………………………..8  
1.2 Bacterial Effector Proteins…….……………………………………..9 
 1.3  APK Signaling……..………………………………………………..10 
 1.4  Apoptotic Signaling……………………..…………………………..12 
 1.5  Cell-Penetrating Peptides and TAT-CaM..………………………….13 
 1.6 YopJ Modulaation of Apoptotic Signaling...………………………..15 
 1.7 The TAT-CaM Adaptor System…………………………………….16 
2.  EXPRESSION AND PURIFICATION OF CELL-PENETRATING PEPTIDES 
AND BACTERIAL EFFECTOR PROTEINS…...………………………….20 
 2.1 Introduction…………………………………………………………..20 
 2.2 Materials and Methods……………………………………………….20 
2.2.1 Construction of TAT-CaM Expression Vector………………………20 
 2.2.2 Construction of Bacterial Effector Expression Vectors………………21 
 2.2.3  Transformation of Plasmid into Nova Blue and BL21 (DE3) Cells….21 
 2.2.5 Expression of TAT-CaM….……………………………….………....22 
3 
 
 2.2.6 Expression of Bacterial Effectors……………………………………22 
 2.2.6 Purification of Proteins……………………………………….……...23 
 2.3  Results and Discussion………………………………………………24 
3. BIO-LAYER INTERFEROMETRY AND CELL-PENETRATION 
ASSAY...........................................................................................................28 
 3.1 Bio-Layer Interferometry Assay…………………………………….28 
 3.2 Eukaryotic Cell Culture……………………………………………...29 
 3.3 Intracellular Delivery Assay…………………………………………30 
 3.4 Results and Discussion……………………………………………....31 
4. CELL DEATH ASSAYS…………………………………………………….45 
4.1  Preparation of Treatments and Controls……………………………..45 
4.2 Treatment of Cells……………………………………………………46 
4.3 Analysis of LDH Activity……………………………………………46 
4.4 Results and Discussion……………………………………………….46 
5. FUTURE DIRECTIONS……………………………………………………..49 
  5.1 Reproducing Positive Uptake Results……………………………49 
  5.2 Reproducing Positive Cell Death Results………………………..49  
5.3 Further Exploration of Effector Pathways…………….…………50 
5.4 Other Bacterial Effectors…………………………………………………..50 
4 
 
5.5 Summation of Future Work Required…………………………………..…50 
5. REFERENCES………………………………………………………………...52 
 
LIST OF FIGURES 
Figure 1: Structure of Type-III Secretion Systems…………………………………….8 
Figure 2: Canonical MAPK Signaling Pathways……………………………………..11 
Figure 3: YopJ Activation of MAPK Pathways………………………………………12 
Figure 4: YopJ Activation of the Apoptotic Pathway………………………………..16 
Figure 5: The TAT-CaM Adapter System……………………………………………19 
Figure 6: Structural Analysis of YopJ………………………………………………..25 
Figure 7: Expression of YopJ and VopA………………………………………..…..26 
Figure 8: Purification of Effectors (YopJ)…………………………………………..27 
Figure 9: Biolayer Interferometry………………………………………………..….28 
Figure 10: Association of YopJ to TAT-CaM……………………………………….32 
Figure 11: Dissociation of YopJ from TAT-CaM…………………………….……..35 
Figure 12: Uptake in the absence of delivery vehicle………………….……………37 
Figure 13: Uptake of YopJ in BHK cells…………………………………………….38 
Figure 14: Orthogonal Projection of YopJ Uptake with TAT-CaM…………………40 
5 
 
Figure 15: Uptake of YopJ in the Absence of TAT-CaM……………………………40 
Figure 16: Orthogonal Projection of YopJ Uptake in the Absence of TAT-CaM.......41 
Figure 17: YopJ Uptake in SiHa Cells……………………………………………….43 


















A major role of the mitogen activated protein kinase (MAPK) pathway in 
eukaryotes is to activate the bacterial pathogen defense response upon the detection of 
bacterial products in the environment. This defensive signaling results in the induction of 
inflammation, the transcription of antimicrobial peptides, the modulation of the cell cycle 
and cell survival. Some Gram-negative bacteria have evolved needle-like structures 
called Type III Secretion Systems (T3SS) that secrete signal-altering molecules into the 
host cell to interrupt signaling pathways that would otherwise lead to the elimination of 
the bacterial infection. These signal-altering molecules are known as bacterial effector 
proteins (BEPs). Bacterial effectors YopJ and VopA have been shown to interfere with 
specific signaling molecules in the MAPK pathway; effectively inducing apoptosis in 
mammalian intestinal endothelial cells. In this study, we deliver these proteins to colon 
cancer cells to artificially induce cell death, using a novel cell-penetrating peptide (CPP) 
delivery system called TAT-CaM. Here, we show that the TAT-CaM system is capable 
of delivering YopJ into mammalian cells and that YopJ is capable of inducing cell death 
once delivered. Although we encountered issues with reproducibility, we believe that 
TAT-CaM-YopJ could be effective in inducing cell death in cancer cells in a 











Under normal conditions, bacterial infection of eukaryotic tissues results in the 
induction of an immune response that leads to the elimination of the bacteria. Bacterial 
byproducts are detected by transmembrane pattern recognition receptors (PRRs) on the 
cell surface. After recognizing bacterial byproducts, these receptors activate signaling 
cascades that result in the transcription of antimicrobial and proinflammatory genes that 
work together to rid the tissue of infection. However, certain species of Gram-negative 
bacteria have developed specialized apparatus called Type III Secretion Systems (T3SS) 
to overcome this defensive mechanism. These needle-like structures are used to secrete 
various signal-altering molecules, known as bacterial effector proteins (BEPs), into the 
cells of the host tissue to interrupt signaling pathways, such as the mitogen-activated 
protein kinase (MAPK) pathway [1, 2, 3]. Interrupting these pathways shuts down 
transcription of defensive genes that would otherwise lead to the elimination of the 
infection [1, 2, 3]. Thus, T3SSs and bacterial effector proteins are adaptations that arose 





Figure 1: Structure of Type-III Secretion Systems.  
 
1.1 Type-III Secretion Systems: 
The T3SS injectosome apparatus consists of several different proteins that form 
basal body rings, a connecting segment and a needle [24]. The hydrophobic rings position 
the structure in the cell membranes of the bacterium, as well as the membrane of the host 
cell. The needle is composed of many subunits of a single protein that come together to 
form a tubular structure through which effector proteins pass into the host cell [24]. At 
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the very base of the basal body lies an export gate whose job is to open and close to allow 
the BEPs to flow through. The exact trigger that controls the opening of the export gate is 
not yet known; however, it does require that the needle contact the host cell membrane 
[24, 25].  
 
1.2 Bacterial Effector Proteins: 
Injections from some bacterial species contain only a few effectors, while other 
species inject up to several hundred different proteins at a time. Bacterial effector 
proteins perform a wide variety of roles once inside the mammalian cell, but all are 
intended to  aid in bacterial survival. Many bacterial effectors do this by shutting down 
host defense systems like the transcription of antimicrobial peptides or the induction of 
inflammation. While others function to kill the host cell so that the bacterium can absorb 
its nutrients.. Many BEPs modulate apoptotic pathways to induce apoptosis in a variety 
of cell types. These effectors are almost always crucial for virulence and gene knockout 
results in complete avirulence.  
The pathogen responsible for plague diseases, Yersinia pestis, has been shown to 
contain 14 bacterial effector proteins. The most well studied of these effectors is YopJ, a 
protein that is capable of modulating MAPK pathways and inducing apoptosis in a 
variety of mammalian cells. Another protein in the YopJ family, VopA is found in Vibrio 
species and performs many of the same functions as YopJ, but is less effective at 
inducing apoptosis. This study focuses primarily on these two proteins and their potential 




1.3 Canonical MAPK Signaling: 
The MAPK pathway regulates cell growth, division, differentiation, stress 
response and apoptosis through signaling cascades that result in the activation of 
transcription factors and other protein kinases [11, 12]. These cascades are composed of 
three families of mitogen-activated protein kinases: MAP3Ks, MAPKKs and MAPKs 
[12]. MAP3Ks are activated via phosphorylation by cell surface receptors after they have 
detected external stimuli and undergone a conformational change. These external stimuli 
include bacterial byproducts and growth factors. Once activated by the cell surface 
receptor, MAP3Ks activate MAPKKs. The now active MAPKKs go on to activate 
MAPKs. Once active, MAPKs work together to modulate the aforementioned cellular 
functions by activating and repressing the transcription of various proteins as well as 






Figure 2: Canonical MAPK Signaling Pathways.  
 
Mitogen-activated protein kinases are serine/tyrosine specific and their targets 
contain an activation loop motif with a serine and tyrosine that must both be 
phosphorylated for the enzyme to become active.  
MAPK pathways are incredibly complex and often cross-talk between one 
another. This means that the activation of one kinase can lead to a variety of different 
effects. Often times, one kinase will activate multiple signaling intermediates, resulting in 
the simultaneous activation and repression of a single cellular mechanism like apoptosis. 
Since the activation of one enzyme can lead to the activation of multiple pathways that 
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oppose one another, the resulting cellular action is often determined by the degree to 
which each pathway is stimulated. Therefore, rather than working like an on/off switch, 
many cellular mechanisms that are controlled by the MAPK signaling pathway function 
on an intensity scale [43]. 
 
1.4 YopJ and VopA Modulation of the MAPK Pathway: 
 
 




VopA and YopJ are bacterial effector proteins that are found in V. 
parahaemolyticus and Yersinia pestis species, respectively, that interrupt MAPK 
signaling cascades by acetylating several MAPKKs, including ERK, p38 and JNK 
[Figure 3]. In the absence of YopJ and VopA, toll-like receptors (TLRs) on the cell 
surface would detect the presence of bacterial byproducts and recruit Raf, MLK3 and 
TAK1. These MAP3Ks would continue the phosphorylation cascade resulting in 
downstream effects that decrease cell growth and differentiation, while increasing  
 
YopJ and VopA acetylate MAPKKs in order to stop the signaling cascade before 
it is able to initiate a defensive against the bacteria. YopJ has been shown to acetylate the 
activation loop of MAPKK6 with the help of acetyl coenzyme A (Acetyl CoA) [23]. In 
this way, YopJ mediated acetylation directly competes with phosphorylation. Through 
this mechanism, YopJ slows or inhibits MAPK signaling pathways in order to facilitate 
bacterial evasion of host elimination [1, 2, 3].  
 
1.5 Canonical Apoptotic Signaling: 
 Apoptosis is programmed cell death and can occur as a result of many different 
triggers. It is initiated in many tissues during development when structures must be 
formed by the removal of cells from an area. For example, the hand develops first with 
webbed fingers until apoptosis is initiated in specific cells, removing tissue from the 
space between each bone to allow the formation of fingers [46]. Apoptosis can also be 
initiated in response to viral infection in order to kill off infected cells to attempt to stop 
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the spread of the virus [47]. Apoptosis is less common under conditions of bacterial 
infection, but some gram-negative bacteria utilize bacterial effectors to initiate apoptosis 
in immune cells to avoid elimination [2, 10]. 
 Apoptotic signaling is dependent on caspases; proteins that activate one another 
through cleavage and initiate signaling cascades that result in the transcription of cell-
death genes and the release of cytotoxic molecules. Apoptotic signaling can be split into 
two major pathways, the intrinsic and extrinsic pathways [46, 48]. 
The intrinsic apoptotic pathway is canonically triggered by interactions within the 
cell. This pathway is most often activated by molecules that are able to cross the cell 
membrane, radiation (DNA damage), hypoxia or a lack of growth factors [46]. When one 
of these triggers is detected, proteins called Bax and Bak come together to form pores in 
the mitochondrial membrane [48]. These pores allow for the release of cytochrome C. 
Cytochrome C then forms a complex with procaspase-9 and Apaf-1 called the 
apoptosome. The apoptosome is responsible for cleaving procaspase-9 into its active 
form, caspase-9, which then cleaves procaspase-3 into caspase-3. Caspase-3 is known as 
the major effector caspase because it is responsible for carrying out functions such as 
initiating the transcription of proteins that lead to cell death [46, 48]. 
The extrinsic apoptotic pathway is activated by a wide variety of extracellular 
ligands that bind to death receptors on the outside of the cell, causing a conformational 
change [46]. This conformational change results in the recruitment of the DISC complex. 
procaspase-8 binds to the DISC complex, is cleaved and dimerizes to form caspase-8. 
caspase-8 then cleaves procaspase-3 into caspase-3. Thus, both the intrinsic and extrinsic 
apoptotic pathways result in caspase-3 activation and rely on its ability to induce cell 
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death. Caspase-8 has a second function that is to cleave tBID into BID. BID then 
oligomerizes Bak which, together with Bax [46], forms pores in the mitochondrial 
membrane, initiating the intrinsic apoptotic pathway. Thus, activation of the extrinsic 
apoptotic pathway results in the downstream activation of the intrinsic apoptotic pathway 
[46, 49]. 
 
1.6 YopJ Modulation of Apoptotic Signaling: 
In addition to modulating MAPK signaling, YopJ has also been shown to activate 
both the intrinsic and extrinsic apoptotic pathways [22]. It first initiates the extrinsic 
apoptosis pathway by activating the death receptor, DISC or Procaspase 8; leading to the 
activation of caspase 8. Caspase 8 then truncates BID to activate the intrinsic pathway 
[Figure 4]. Prior experiments have shown that the YopJ mechanism of apoptotic 
induction is rapid and efficient [2]. Because of this ability, it was selected as the major 





Figure 4: YopJ Activation of the Apoptotic Pathway. Original Image modified from 
Galluzzi et al., 2009 [6]. YopJ has been reported to activate the extrinsic apoptotic 




1.7 The TAT-CaM Adaptor System: 
Cell penetrating peptides are short peptide sequences that can cross the cell 
membrane. Our technology was developed around TAT, a CPP that is native to the HIV 
virus. A wide variety of cargo proteins can be bound to TAT and pulled into the cell with 
it. The problem with ordinary CPP delivery is that the cargo remains attached to TAT and 
cannot escape the endosome that TAT is bound to after endocytosis [5]. Our technology 
overcomes the obstacle of endosomal entrapment by incorporating calcium-dependant 
binding through a protein called calmodulin (CaM) [Figure 6]. CaM is attached 
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covalently to TAT just like any other cargo. However, a user defined cargo protein 
encoded with a Calmodulin Binding Site (CBS) can then be bound to CaM in a calcium 
dependent fashion. Calmodulin binds the cargo tightly in the presence of calcium but 
releases the cargo when calcium concentrations are low. Since intracellular 
concentrations of calcium are natively low, this mechanism works very well for the 
delivery of cargo into cells [4, 5]. The TAT-CaM complex binds tightly to the cargo 
outside of the cell where calcium concentrations are high. Once the complex enters the 
cell in an endosome, calcium inside the endosome begins to flow down the concentration 
gradient and into the cytoplasm, which has a lower calcium concentration than the 
extracellular environment. Once calcium concentrations drop to a low enough level 
within the endosome, the CBS tag on the cargo protein no longer binds tightly to TAT-
CaM and the cargo protein is released into the cytoplasm of the cell, while TAT-CaM 












Figure 5: The TAT-CaM Adapter System.  A. Calmodulin binds tightly to the CBS tag 
on the protein in the presence of calcium. B. Calmodulin dissociates from the CBS tag on 
the cargo protein as endosomal calcium levels lower and approach homeostasis with the 
internal cellular environment. 
 
Our goal is to utilize this TAT-CaM system to deliver bacterial effector proteins 
YopJ and VopA into the cytoplasm of cancer cells, where they have been shown to 
induce apoptosis [1, 2, 3]. We believe that our system will be an effective method of 
delivery as it has been shown to work in the past with other cargos of various sizes and 



















We propose a method for the cytoplasmic delivery of bacterial effector proteins 
VopA and YopJ to colon cancer cells in order to interrupt the MAPK pathway. Based on 
previous research by Rheinallt M. Jones et al. [2, 3], we believe that this will initiate 
apoptosis, resulting in the death of the colon cancer cells. Although these proteins have 
been shown to inhibit the MAPK pathway resulting in reduced cell growth, they have not 
been utilized against cancer cells due to the lack of an efficient delivery mechanism that 
does not require infection by a bacterial pathogen. We hope to overcome this obstacle by 
utilizing cell penetrating peptide (CPP) technology [4, 5].  
In order to begin our experiments, we needed to prepare pure TAT-CaM, as well 
as pure effector proteins containing the CBS tag. In addition to purifying the YopJ 
protein, we analyzed it using several bioinformatics tools to further understand how it 
works. 
 
2.2 Materials and Methods: 
2.2.1 Construction of TAT-CaM Expression Vector: 
To generate pure protein for use in experiments, the protein expression vector 




2.2.2 Construction of Bacterial Effector Expression Vectors: 
 To generate pure protein for use in experiments, a protein expression vector was 
constructed and ordered from GeneWiz [50]. The pET-19b vector was modified with a 6-
residue histidine tag for purification and  the gene of interest at the N-terminus. The gene 
of interest was cloned into the vector using NdeI and BamHI restriction endonuclease 
sites. 
 
2.2.3 Transformation of Plasmid into Nova Blue and BL21 (DE3) Cells: 
We received 2g of lyophilized plasmid containing the desired construct. The 
plasmid was then dissolved in elution buffer (10 mM Tris-HCl, pH 8.5 and 0.1 mM 
EDTA). Frozen competent cells were thawed on ice for 5 to 10 min. After the addition of 
50-100ng of plasmid DNA to the competent cells, they were incubated on ice for 30 
minutes. The cells were then placed in a 42°C heat bath for 1 minute before being 
transferred to an ice bucket for 2 minutes. 1mL of Luria-Bertani (LB) broth was added to 
the cells and they were incubated at 37°C for 1 hour, while shaking. The cells were then 
concentrated to a volume of 150uL and were plated on an ampicillin/tetracycline resistant 
LB agar plate and incubated overnight at 37°C. Overnight cultures of Nova Blue cells 
were prepared in order to maintain stocks of DNA. These cultures were prepared by 
inoculating 5mL of LB medium with a single fresh colony and this was allowed to grow 
overnight at 37°C, shaking at 220rpm. DNA was then mini-prepped from these cells to 





2.2.4 Expression of TAT-CaM: 
An overnight culture was prepared by inoculating 50mL of LB medium 
(containing ampicillin and chloramphenicol) with a single fresh colony and allowing it to 
grow overnight at 37°C. In the morning, 10mL of this culture was added to 1L of LB 
medium (containing ampicillin and chloramphenicol) and allowed to grow at 37°C. 
Optical density measurements were taken until the culture achieved an absorbance level 
between 0.4 and 0.6 when read at 600nm. The temperature was lowered to 30°C and the 
cells were induced with 0.2 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG, Sigma-
Aldrich). Cells were induced for 4-6 hours before harvesting. Cultures were harvested 
using a Sovall R 5C plus centrifuge spinning at 7000 rpm at 4°C before being decanted 
and stored at -80°C for later purification. 
 
2.2.5 Expression of Bacterial Effectors: 
An overnight culture was prepared by inoculating 50mL of LB medium 
(containing ampicillin and chloramphenicol) with a single fresh colony and allowing it to 
grow overnight at 37°C. In the morning, 10mL of this culture was added to 1L of LB 
medium (containing ampicillin and chloramphenicol) and allowed to grow at 37°C. 
Optical density measurements were taken until the culture achieved an absorbance level 
between 0.4 and 0.6 when read at 600nm. The temperature was lowered to 25°C and the 
cells were induced with 0.2 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG, Sigma-
Aldrich). Cells were induced for 4-6 hours before harvesting. Cultures were harvested 
23 
 
using a Sovall R 5C plus centrifuge spinning at 7000 rpm at 4°C before being decanted 
and stored at -80°C for use in purification. 
 
2.2.6 Purification of TAT-CaM and Bacterial Effectors: 
Cells were resuspended in 25mL of lysis buffer (10mM Tris-base pH 8.0, 10mM 
imidazole, 0.05% Tween, 500mM NaCl, 10% glycerol) with the help of a vortex and a 
homogenizer. DNase and lysozyme were added to break down DNA and cell membranes, 
respectively. The homogenized lysates were then run through a French press to rupture 
the cell membranes and release cellular contents into the supernatant. The lysates were 
then separated into supernatant and lysate pellets by centrifugation at 18,000 rpm. 
Proteins in the soluble supernatant were purified by His-tag affinity chromatography. 
Talon metal affinity resin (ClonTech laboratories, CA, USA) was used according to the 
manufacturer's instructions. 3mL of resin/storage solution mixture was centrifuged to 
remove the storage solution. Then, the resin was equilibrated in  lysis buffer (10mM Tris-
base pH 8.0, 25mM imidazole, 0.05% Tween, 500mM NaCl, 10% glycerol) by washing 
three times with 3mL. The resin was then resuspended in 3mL of lysis buffer added to the 
supernatant and rocked at 4°C for 45 minutes to allow binding to occur. The protein-resin 
complex was then poured into a gravity column and washed with 10mL of wash buffer 
(10mM Tris-base pH 8.0, 25mM imidazole, 0.05% Tween, 500mM NaCl, 10% glycerol) 
three times. The protein of interest was then eluted with elution buffer (10mM Tris-base 
pH 8.0, 250mM imidazole, 0.05% Tween, 500mM NaCl, 10% glycerol) in ten 1mL 
elutions. Excess salts were removed from the product via FPLC buffer exchange through 
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a desalting column into NEB buffer (10mM Hepes, 150mM NaCl, 1mM CaCl2, 10% 
Glycerol, 1mM DTT). Purified protein products were stored at -80°C. 
 
 
2.3 Results and Discussion:  
In order to better understand the functionality of YopJ, it was analyzed using 
Jpred4 and Scansite. This software identified the predicted secondary structure of YopJ 
as well as two active sites in the protein. The first is a phosphoserine/threonine binding 
site and the second is a kinase binding site. These two sites help to confirm the theory 
that YopJ is a serine/threonine acetyltransferase that acts on kinases. 
 
A.  
        10         20         30         40         50 
MIGPISQINI SGGLSEKETS SLISNEELKN IITQLETDIS DGSWFHKNYS  
        60         70         80         90        100 
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       110        120        130        140        150 
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       160        170        180        190        200 
YQLPDCHFSM VEMDIQRSSS ECGIFSFALA KKLYIERDSL LKIHEDNIKG  
       210        220        230        240        250 
ILSDGENPLP HDKLDPYLPV TFYKHTQGKK RLNEYLNTNP QGVGTVVNKK  
       260        270        280  








Figure 6: Structural Analysis of YopJ. A. DNA sequence of Yersinia pestis YopJ 
acquired via UniProt. B. Secondary structure prediction acquired via Jpred4 [45]. Helices 
in red, B-sheets in green. C. Functional domain prediction using Scansite [44]. A 
phosphoserine/threonine binding site and a kinase binding site were identified. This 
supports the theory that YopJ has serine/threonine acetyltransferase activity towards 






Figure 7: Expression of YopJ and VopA. The molecular weight marker used is 
Precision Plus Protein Dual Color [51]. The first two lanes show VopA expression, the 
third and fourth two lanes show YopJ expression. Lanes marked “U” are uninduced and 
should not show a band at the indicated size. Lanes marked “I” contain samples that have 
been induced and a band should appear at 38.8kD. Expression of VopA was unsuccessful 
and very small amounts of the protein were produced. Expression of YopJ was more 
effective and a band can be seen at 38.8kD. However, neither proteins were expressed in 





                                                                                                                       
Figure 8: Purification of Effectors (YopJ). The molecular marked used is Precision 
Plus Dual Color Standard [51]. Full length protein can be seen at 38.8kD. However, two 
breakdown products were copurified. 
  
 Effector purification proved to be far more difficult than anticipated. Breakdown 
products that contained the His-Tag were purified alongside of the full-length protein. 
These products can be seen in the elutions of Figure 8. In an attempt to reduce the amount 
of breakdown product present, all purification steps were performed in a room that 
maintains 4°C and with the addition of 2mM 2-Mercaptoethanol as a reducing agent. 








3. BIO-LAYER INTERFEROMETRY AND INTRACELLULAR DELIVERY 
ASSAY 
 
3.1 Bio-Layer Interferometry: 
Biolayer interferometry is a biosensing technique that operates in real time. One 
molecule, the ligand is tethered at the tip of the optical biosensor. White light travels 
down to the molecule and reflects off. The interference pattern is measured as a shift in 
wavelength. Once a baseline has been established, the senor is then moved into an analyte 
containing buffer to monitor association and finally moved into an analyte free buffer to 
measure dissociation. Binding of both the ligand and the analyte on the sensor increases 
the reflecting surface hence causing a coincident change in the interference pattern 
 
 
Figure 9: Biolayer Interferometry. A. An interference pattern is established by 
reflection of white light from two surfaces on a fiber optic sensor with biotinylated 
molecules attached to the biolayer. B. Binding of analyte molecules causes a shift in the 
wavelength of the interference pattern. C. Monitoring of the interference shift over time 
reflects association of analyte with the immobilized molecule. Association is measured in 
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the presence of analyte and dissociation is measured when the sensor is moved to buffer 
containing no analyte. Image from ForteBio.com. 
 
The kinetics of the TAT-CaM-Cargo system were assessed via bio-layer 
interferometry using a FortéBio Octet QK biosensor with treptavidin sensors (SA). 
Assays were performed in black 96-well microplates at 25°C. All volumes were 200µL. 
TAT-CaM was biotinylated using NHS-LC-LC-biotin (succinimidyl-6-[biotinamido]-6-
hexanamidohexanoate) (Thermo Scientific, Rockford, IL, USA) at a 10:1 molar ratio of 
biotin to protein for 30 min at 25°C. Biotinylated TAT-CaM was then loaded onto the 
streptavidin sensor and a baseline of the interference pattern was established prior to 
associating ananalyte (CBS-YopJ). Dissociation was subsequently analyzed by moving 
the sensor to a well that contained no free analyte to determine how well the complex 
stays together  Next, the sensor was moved to a well containing 10mM EDTA to mimic 




3.2 Eukaryotic Cell Culture: 
 
Starting BHK 21 and SiHa (HTB-35) ATCC Cell Lines:  
Cells were removed from liquid nitrogen storage and placed in a 37°C bead bath 
for 2 minutes and then warmed in the hand and closely monitored until they thawed. The 
cells were then transferred into a 15mL conical tube containing 5mL of Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS). Cells 
were centrifuged for 5 minutes at 1000 rpm at 30°C. Cells were then re-suspended into 
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12mL of pre-warmed growth media at 37°C and then transferred into a T-75 flask. Cells 
were then returned into the incubator to be incubated at 37°C under 5% carbon dioxide 
atmosphere conditions.  
 
Sub-culturing BHK and SiHa cells:  
Cells were maintained as they grew through regular media changes. When cells 
were maximally between 80-90% confluent in a T-75 flask, the culture medium was 
removed and discarded. The cell layer was quickly rinsed with 0.25% (w/v) Trypsin-
0.1% EDTA solution to remove all traces of serum which contains trypsin inhibitors. 
1mL of Trypsin-EDTA solution was added into the flask and it was placed in the 37°C 
incubator for 5 minutes and cell dispersion was periodically observed under a light 
microscope. Once the cell population was detached from the surface of the flask, 9mL of 
growth media was added into the T-75 flask and was pipetted gently to mix. 2mL of the 
cells in suspension were added to a new T-75 flask containing 10mL of sterile growth 
media. Cells were also plated in chambered Lab-Tek 4-well cover glass slides (Fisher 
Scientific) at 50% confluence for intracellular delivery experiments.  
 
3.3 Intracellular Delivery Assay: 
Cells were seeded in three wells of a 4-well Lab-Tek chambered cover glass 
(Fisher Scientific) at 50% confluence in DMEM medium supplemented with 5% FBS and 
cultured overnight. The medium was discarded and replaced with fresh medium. TAT-
CaM and CBS-Cargo were combined and allowed to incubate on ice for 5-10 minutes. 
The TAT-CaM Cargo complex was then diluted in media to a concentration of 1uM. 
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Cargo by itself was also diluted to 1uM in media. One well was treated with the TAT-
CaM-Cargo complex, another was treated with the cargo alone and the third well was an 
untreated control. The chamber culture plate was incubated for 1 hour at 37°C in a 5% 
CO2 atmosphere. Cells were rinsed three times with PBS containing calcium and 
magnesium. The cells were treated with 2 µM cell tracker green dye (Thermo Fisher) for 
20 min with incubation followed by three rinses with PBS. Cells were stained with a drop 
of NucBlue for 10min at 37°C. After three washes with PBS, DMEM/5% FBS medium 
containing 25mM HEPES pH7.4 buffer was added into the chambers. Penetration was 
analyzed using confocal microscopy.  
 
3.4 Results and Discussion: 
 Before intracellular delivery assays could be performed, the functionality of the 
TAT-CaM-YopJ adaptor system had to be assessed. Biolayer interferometry was used to 
confirm this. As seen in figure 10, YopJ bound tightly to TAT-CaM in the presence of 
calcium and did not dissociate easily. However, figure 11 demonstrates that when 
calcium is removed from the environment, rapid dissociation of the complex occurs. Thus 




Figure 10: Association of YopJ to TAT-CaM. YopJ binds to TAT-CaM with high 
affinity in the presence of calcium. This data represents the change in the interference 
pattern recorded by the ForteBio Octet K2 when YopJ binds to TAT-CaM which is 





Figure 11: Dissociation of YopJ from TAT-CaM. YopJ rapidly dissociates from TAT-
CaM in the absence of calcium. This data represents the shift in the interference pattern 
recorded by the ForteBio Octet K2 when YopJ releases from TAT-CaM which is bound 
to a streptavidin sensor upon introduction of 0.1mM EDTA. EDTA binds up the calcium 
in solution, mimicking the low calcium conditions found in the cytoplasm of eukaryotic 




Many cellular delivery experiments resulted in the uptake of YopJ into the cell 
not only when it was bound to TAT-CaM. but also when cells were treated with YopJ 





















Figure 12: Uptake of YopJ into BHK cells in the absence of delivery vehicle. YopJ 
was labeled with DyLight 550 red fluorescent tag. The cytoplasm was stained with 1mM 
CellTracker Green (Thermo Fisher Scientific). The nuclei were stained with NucBlue 
LiveReady Probes (Thermo Fisher Scientific). The cytoplasmic dye can be seen entering 
the nucleus and the labeled YopJ entered the cytoplasm without a delivery vehicle. A and 




 Nuclear staining revealed that a bacterial infection was present in the BHK cell 
line. It is likely that these small bacteria were mycoplasma. Mycoplasma are a genus of 
small bacteria that lack cell walls surrounding their membranes and often enter into 
eukaryotic cells as parasites [52]. Due to the lack of a cell wall, they are unaffected by 
common antibiotics that target bacterial cell walls. Thus, in order to combat this 
contamination problem, all infected cells were thrown away, the hoods and culture 
materials were thoroughly disinfected, and new cell lines were started. However, further 
tests for mycoplasma showed that it was still present in some cells. The disinfecting of 
lab equipment and restarting of cell lines was performed several times until cells tested 





Figure 13: Uptake of YopJ in BHK cells. YopJ was labeled with DyLight 550 red 
fluorescent tag. The cytoplasm was stained with 1mM CellTracker Green (Thermo Fisher 
Scientific). The nuclei were stained with NucBlue LiveReady Probes (Thermo Fisher 
Scientific). YopJ is rendered in white. A. cytoplasm only. B. YopJ only. C. Nucleus only. 
D. Superimposed image of all three channels. 
 
YopJ cellular delivery assays in BHK cells were performed once more after the 
mycoplasma infection was cleared. The cells looked haelthy and YopJ appeared to be 





Figure 14: Orthogonal Projection of YopJ Uptake with TAT-CaM. This orthogonal 
projection shows the three-dimensional view of the cell. YopJ was labeled with DyLight 
550 red fluorescent tag. The cytoplasm was stained with 1mM CellTracker Green 
(Thermo Fisher Scientific). The nuclei were stained with NucBlue LiveReady Probes 
(Thermo Fisher Scientific). YopJ is rendered in white. 
 
In order to support the theory that that the protein was entering into the inside of 
the cell, a Z-stack was taken. This is a confocal microscopy technique in which several 
images are taken at different points along the Z-axis of the cell and the individual images 
are rendered in an orthogonal projection. This method allows one to look at each image to 
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determine if the protien is present at that depth in cell. The rendering in Figure 14 
suggests that YopJ is likely inside the cell. 
When the cells were unheathly, YopJ was able to enter into the cytopolasm 
without the help of TAT. A no TAT control was performed to see if YopJ would still be 
able to enter the cell without a delivery vehicle. Results were often mixed and YopJ was 
sometimes able to enter the cell without TAT-CaM and other times could not. In the 
experiments where YopJ entered without TAT-CaM, the cells were usually visibly 
unhealthy. When cells were healthy, YopJ entered the cells only in the presence of TAT-
CaM [Figures 14 and 15 vs. Figures 16 and 17]. When the experiment was performed 





Figure 15: Uptake of YopJ in the Absence of TAT-CaM. YopJ was labeled with 
DyLight 550 red fluorescent tag. The cytoplasm was stained with 1mM CellTracker 
Green (Thermo Fisher Scientific). The nuclei were stained with NucBlue LiveReady 
Probes (Thermo Fisher Scientific). A. Cytoplasm only. B. YopJ only. C. Nucleus only. D. 







Figure 16: Orthogonal Projection of YopJ Uptake in the Absence of TAT-CaM. 
YopJ was labeled with DyLight 550 red fluorescent tag and was rendered in white. The 
cytoplasm was stained with 1mM CellTracker Green (Thermo Fisher Scientific). 
 
 These experiments were then repeated in SiHa cells, a human cervical cancer cell 
line, to determine whether or not YopJ could be delivered into epithelial cancer cells. 
Once again, YopJ was being taken up into the cells without the addition of TAT-CaM 
and the cells looked visibly distressed. A mycoplasma test revealed that the 
contamination was also in the SiHa cell line. So, the cells were discarded and the 
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laboratory equipment was disinfected. Several cycles of this disinfecting had to be 
performed before the cells tested mycoplasma-free.  
 
Once the cells were clear of infection, the uptake assays were repeated in these 
cells. Figure 18 shows a side by side comparison of the delivery of YopJ by itself and 
YopJ in the presence of TAT-CaM in SiHa cells. Once again, the system was effectively 
delivering the protein into the cells only in the presence of TAT-CaM.  
Despite obtaining positive results, data replication was a large obstacle. Cell 
health as well as other unknown factors caused the effector proteins to enter the cell 
without the presence of TAT-CaM. Perhaps with better cell culturing techniques and a 






Figure 17: YopJ Uptake in SiHa Cells. YopJ was labeled with DyLight 550 red 
fluorescent tag. The cytoplasm was stained with 1mM CellTracker Green (Thermo Fisher 
Scientific). The nuclei were stained with NucBlue LiveReady Probes (Thermo Fisher 
Scientific). A. Cells that were treated with YopJ alone (no TAT-CaM). B. Cells that were 
treated with TAT-CaM-YopJ. These images suggest that YopJ is able to penetrate into 























4. CELL DEATH ASSAYS 
 
In order to quantify cell death resulting from TAT-CaM-Effector treatment, LDH 
assays were performed. LDH assays utilize lactase dehydrogenase (LDH) in the media as 
a measure of cell death. When cells die, membranes are compromised and LDH is 
allowed to leak into the media. The amount of LDH released per cell is remarkably 
uniform across a given cell type. Thus, it can be used to quantify what percentage of a 
cell population is dead. LDH in the media can be measured via a fluorometric assay that 
utilizes a fluorophore or via a colormetric assay that measures LDH reactivity with a 
substrate. We opted for the latter and chose the Pierce LDH cytotoxicity assay kit 
(Thermo Scientific). First, LDH catalyzes the conversion of lactate to pyruvate, resulting 
in NAD+ reduction to NADH. Then, diaphorase utilizes NADH to reduce tetrazolium salt 
(INT) into a red formazan product. The formation of this red formazan product creates a 
color change that can be detected on a microplate reader.  
 
4.1 Preparation of Treatments and Controls: 
TAT-CaM-Cargo: 
 Purified TAT-CaM and a purified bacterial effector were thawed in the presence 
of 200nM DTT and combined at a concentration of 10uM in 60uL NEB buffer (10mM 
Hepes, 150mM NaCl, 1mM CaCl2, 10% Glycerol, 1mM DTT). The mixture was allowed 
to incubate on ice for 10 minutes to allow the TAT-CaM-Cargo complex to assemble. 





TAT-CaM Only and Cargo Only: 
 Purified protein was thawed in the presence of 200nM DTT, then serially diluted 
to 10uM in 60uL of NEB buffer (10mM Hepes, 150mM NaCl, 1mM CaCl2, 10% 
Glycerol, 1mM DTT). The protein was then diluted to 1uM via the addition of 550uL of 
sterile growth medium. 
 
4.2 Treatment of Cells 
Cells were cultured in 96-well plates in Dulbecco’s Modified Eagle Medium with 
5% FBS. Experimental wells were treated with 1uM TAT-CaM-Cargo. Control wells 
were treated with 1µM of cargo only, TAT-CaM only or with nothing (no-treatment 
control). Each treatment was performed in triplicate. 
 
4.3 Analysis of LDH Activity 
At each time point, 50uL of media was removed from the cells and placed in a 
new 96-well plate to be tested for LDH content. 50uL of fresh media was then placed on 
the cells. To measure LDH levels in the media collected, 50uL of colormetric agent was 
added and allowed to react for 30 minutes in the dark at room temperature. Following this 
incubation, 100uL stop buffer was added to halt the reaction. Color change was measured 
on a microplate reader at 600nm.  
 
4.4 Results and Discussion: 
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 The initial cell death assay demonstrated a high level of cell death within the first 
hour post-treatment. The levels of cell death in cells treated with TAT-CaM-YopJ was 
not higher than that of the other treatments at the 6 and 24 hour time points due to the 
nature of the assay. In this assay, media is collected and tested after each time point and 
new media is added. The media that was collected from the wells containing TAT-CaM-
YopJ was tested after the first hour and was shown to contain a large amount of LDH, 
indicating that a great deal of cell death occurred in the first hour. However, the LDH that 
had been produced was no longer in the well containing the cells and they failed to 
produce more by the 6 and 24 hour time periods. Thus, it was concluded that YopJ 
induces rapid cell death within the first hour post-treatment, but its effects are not 
dragged out over a long period of time. 
 Like in the intracellular delivery assays, data replication was a major issue with 
these cell death assays. Many times, no cell death was occurring at all. It is likely that this 
is the result of having to use a newer protein prep when the first one ran out. The first 
protein prep was very functional and Figure 19 shows the cell death data obtained from 
treating cells with it. However, none of the other preps produced the same results. So, it is 





Figure 18: TAT-CaM-YopJ induced Cell Death in SiHa Cells. SiHa cells were 
subjected to 1uM treatments and resulting LDH leakage was monitored over a 24 hour 











5. FUTURE DIRECTIONS 
 
5.1 Reproducing Positive Uptake Results: 
This study showed that the TAT-CaM system is capable of delivering bacterial 
effector proteins into mammalian cells without the need for bacterial infection and type-
III secretion systems. Although many experiments resulted in the uptake of effectors 
without the TAT-CaM system, this can most likely be explained by cellular distress. One 
major cause of cell distress that was detected in this study was the presence of 
mycoplasma contamination in both cell lines. However, when the cells were healthy, the 
effectors were able to enter the cells only when bound to TAT-CaM. Thus, TAT-CaM 
seems to be an effective delivery mechanism for bacterial effector proteins. Future 
researchers must be sure to keep their cell lines free of mycoplasma and overall devoid of 
stress. It is likely that this would result in the reproducibility of the positive data obtained 
in this study.  
 
5.2 Reproducing Positive Cell Death Assay Results: 
 This study also showed the ability of TAT-CaM-YopJ to induce rapid cell death 
in epithelial cancer cells within the first hour of treatment. However, reproducibility was 
once again an issue. The issues with reproducibility came after the original protein prep 
was exhausted. Thus, it is likely that a functional prep of YopJ would allow future 




5.3 Further Exploration of Effector Pathways: 
 In addition to reproducing the positive data obtained in this study, it would 
beneficial for a future researcher to pursue the identification of pathway interference by 
YopJ and VopA. While some MAP2Ks that are targeted by these effectors have been 
identified, there is not a comprehensive list of YopJ and VopA kinase interactions. 
 Additionally, the identification of the exact location of YopJ action in the 
apoptotic pathway has yet to be elucidated. It has been shown that YopJ stimulates the 
pathway somewhere between the death receptor and caspase-8. The details of this 
pathway could potentially be discovered through immunoblotting techniques. 
 
5.4 Other Bacterial Effectors: 
 This study focused primarily on YopJ and included some experiments with VopA. 
However, there are hundreds of other bacterial effector proteins out there that could 
potentially be more effective than YopJ or VopA. Therefore, after establishing a 
consistent protocol and a healthy cell line to confirm the data obtained in this study, 
future researchers may benefit from expanding this study to other bacterial effectors in 
the hopes of identifying and even more effective effector with more potential as a cancer 
therapeutic. 
5.5 Summation of Future Work Required: 
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 This study produced data that would suggest that YopJ is able to be delivered into 
cancer cells via the TAT-CaM adaptor system and that this delivery is capable of 
inducing rapid cellular death. However, in order to say that this is the case with certainty, 
these experiments must be replicable. Thus, future research is required to confirm the 
results of this study. 
 Additionally, it is not only important to prove that this system can work, but to 
also be able to explain why it works. Therefore, future research into the pathways by 
which YopJ and VopA act would be highly beneficial. 
 YopJ and VopA are only two bacterial effectors out of hundreds. It may be that 
there are others which would work even more effectively. Therefore, this study could 
also be expanded to include many more bacterial effectors in order to determine the best 
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